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Abstract
The incidence of cancer increases significantly in later life, yet few pre-clinical studies of cancer
immunotherapy use mice of advanced age. A novel vaccine delivery platform (VacciMax®,VM) is
described that encapsulates antigens and adjuvants in multilamellar liposomes in a water-in-oil
emulsion. The therapeutic potential of VM-based vaccines administered as a single dose was tested
in HLA-A2 transgenic mice of advanced age (48–58 weeks old) bearing large palpable TC1/A2
tumors. The VM-based vaccines contained one or more peptides having human CTL epitopes
derived from HPV 16 E6 and E7. VM formulations contained a single peptide, a mixture of four
peptides or the same four peptides linked together in a single long peptide. All VM formulations
contained PADRE and CpG as adjuvants and ISA51 as the hydrophobic component of the water-
in-oil emulsion. VM-formulated vaccines containing the four peptides as a mixture or linked
together in one long peptide eradicated 19-day old established tumors within 21 days of
immunization. Peptide-specific cytotoxic cellular responses were confirmed by ELISPOT and
intracellular staining for IFN-γ producing CD8+ T cells. Mice rendered tumor-free by vaccination
were re-challenged in the opposite flank with 10 million HLF-16 tumor cells, another HLA-A2/E6/
E7 expressing tumor cell line. None of these mice developed tumors following the re-challenge. In
summary, this report describes a VM-formulated therapeutic vaccine with the following
unprecedented outcome: a) eradication of large tumors (> 700 mm3) b) in mice of advanced age c)
in less than three weeks post-immunization d) following a single vaccination.
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Background
Decreased immunity in the elderly has been documented
and associated with decreased T cell differentiation and
aging of naïve T cells, as well as aging of peripheral mem-
ory cells [1-3]. To counter decreasing immunity in the eld-
erly, studies on influenza vaccination have shown that
immune responses in the elderly could be elevated by
designing vaccines with enhanced immunogenicity, by
using strong adjuvants and increasing access to profes-
sional antigen presenting cells. This resulted in stimulat-
ing the Th1 arm of the immune system, and increasing
durable memory T cells [4,5]. We have previously
described such a highly effective single administration
vaccine platform (VacciMax®,VM) that uses liposomes in a
water-in-oil emulsion to deliver a peptide derived from
HPV 16 E7 having a CTL epitope fused to PADRE with
CpG adjuvant [6]. The efficacy of this vaccine platform
was evaluated using a well-described mouse model based
on HPV 16-expressing C3 tumor cells [7]. The present
study used VM in a different tumor model, namely a TC1/
A2 cell line that expresses human class I MHC and HPV16
in HLA A2-mice [8,9]. The aim of this study was to inves-
tigate whether VM-formulated vaccine incorporating
human MHC restricted HPV-16 peptides would be effica-
cious in rejection of large established tumors in human-
ized mice of advanced age.
Methods
Mice and cell lines
Pathogen-free 8–12 week old HLA-A2 transgenic breeding
mice, HLA-A*0201 (C57BL/6-Tg, HLA-A2.1, 1Enge/J,
Jackson Laboratories) were housed under filter top condi-
tions with water and food ad libitum. Institutional animal
care and use guidelines were followed for all experiments.
The mice were maintained until age 48–58 weeks. The
transgenic HLA-A2 mice express the α1,  α2 and α3
domains of HLA-A2.1.
TC1/A2 tumor cells were primary lung epithelial cells co-
transformed with HPV-16 E6, HPV-16 E7, and ras onco-
genes (8). The TC1/A2 tumor cell line was cultured in
RPMI 1640 (Sigma, St. Louis, MO) supplemented with 10
% heat-inactivated fetal calf serum (Hyclone), 2 mM L-
glutamine (Gibco), 5 mM 2-mercaptoethanol (Gibco),
penicillin and streptomycin (100 μg/ml). Cells were incu-
bated at 37°C/5% CO2.
The HLF16 tumor cell line was established from heart and
lung tissue from HLA-A2 Dd mice. HLF16 tumor cells
expresses E6, E7 with a deletion of (E7:_49–57,
RAHYNIVTF). HLF16 tumor cells do not present this very
immunogenic H-2Db epitope therefore, rejection of the
tumor would most likely be mediated by immune
responses against the HLA-A*0201-restricted peptides
(13).
Peptides and oligonucleotides (ODN)
The HLA A*0201 restricted HPV 16 peptides, which have
been previously described [10], were purchased from Dal-
ton Chemical Laboratories Inc. (Toronto, ON, Canada).
The peptide sequences are derived from the E6 and E7
proteins of type 16 HPV and are as follows: (E7:11–20;
YMLDLQPETT), (E7: 82–90; LLMGTLGIV), (E7:86–93;
TLGIVCPI) and (E6:29–38; TIHDIILECV). The peptides
were incorporated in the vaccine as a mixture (25 μg of
each peptide/dose), or as a single fusion protein in which
the 4 peptides are joined together with AAY spacers for
optimal proteosomal cleavage [11]. The resulting long
peptide (hereafter designated AB2) (TIHDIILECVAAYYM-
LDLQPETTAAYLLMGTLGIVAAYTLGIVCPI) was adminis-
tered at 100 μg/dose. All vaccine formulations contained
PADRE (AKXVAAWTLKAAA-OH; 25 μg/dose) and species
specific CpG ODN 1826 (5'-TCCATGACGTTCCT-
GACGTT-3', Coley Pharmaceutical, Wellesley, MA) at 50
μg/dose.
Tumor challenge
Mice were challenged with TC1/A2 tumor cells (105 cells/
mouse) implanted subcutaneously in the left flank.
Tumor size was measured every 5 days and is reported as
the average tumor size in five mice or as tumor size in
individual mice. Sixty days post-TC1/A2 implantation,
tumor free mice were re-challenged in the opposite flank
by 107 HLF16, a heart and lung fibroblast tumor cell line
transfected with E6, E7 that lacks the H-2 brestricted HPV
16 E7 49–57 epitope forcing all the T cell responses to rec-
ognise these tumor cells only through HLA-A*0201
restriction [12,13].
Therapeutic immunization
Nineteen days post-TC1/A2-challenge, mice (5 mice/
group) received a single subcutaneous (s.c.) injection of
vaccine containing either the four peptides, the AB2 pep-
tide or E7:82–90 alone. The HPV E6/E7 peptides were
encapsulated in VM as previously described [6]. In brief,
lecithin and cholesterol in a ratio of 10:1 (0.2 g lecithin
and 0.02 g cholesterol/dose) were dissolved in chloro-
form/methanol (1:1; v/v) and the solution was filter-ster-
ilized using a PTFE 0.2 μm filter. Chloroform and
methanol were removed under reduced pressure using a
rotary evaporator and traces of the solvents were removed
from the resulting thin lipid layer in vacuo. For liposome
encapsulation, peptides with CpG and PADRE were dis-
solved in sterile PBS and the resulting solution added to
the thin lipid layer with mixing to form liposomes. The
resulting suspension of liposomes was emulsified in Mon-
tanide ISA51 (Seppic, France) by adding the liposome/
PBS suspension to ISA51 to form a water-in-oil emulsion
(PBS:ISA51; 1:1,v/v; 100 μl/dose). Control mice were
injected with vaccine that contained all components ofJournal of Translational Medicine 2007, 5:26 http://www.translational-medicine.com/content/5/1/26
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the test vaccines except liposomes, CpG ODN alone or
phosphate buffered saline (PBS, 100 μL/injection).
Ex vivo analysis of antigen-specific T cells by ELISPOT
Activated antigen-specific cytotoxic T-cells in splenocytes
harvested from immunized C57BL/6 mice were detected
using the BD ELISPOT kit following the instruction man-
ual (BD Bioscience, San Diego, CA). Briefly, on day 8 post-
immunization, a 96-well nitrocellulose plate was coated
with capture antibody, a purified anti-mouse IFN-γ anti-
body, by incubation overnight at 4°C, then blocked with
complete media. Splenocytes were added to wells at an
initial concentration of 106 cells/well in a volume of 100
μl and a row of serial dilutions prepared. Cells in a dilu-
tion series were either unstimulated or stimulated with
relevant or irrelevant peptides (10 μg/ml).
PMA (5 ng/ml, Sigma) and ionomycin (500 ng/ml,
Sigma), served as positive controls and irrelevant peptide
and media alone served as negative controls. The plate
was incubated overnight at 37°C/5% CO2. Next day, the
plate was incubated with detection antibody (a bioti-
nylated anti-mouse IFN-γ antibody), for 2 hours at room
temperature. Unbound detection antibody was removed
by washing and the enzyme conjugate (Streptavidin-HRP)
was added. Following 1 hour incubation at room temper-
ature, unbound enzyme conjugate was removed by wash-
ing and the plate was stained with an AEC substrate
solution for 20 minutes. The plate was washed, allowed to
air dry overnight, and foci of staining were counted using
a magnifying lens.
Intracellular cytokine staining
Spleens from mice were removed and splenocytes har-
vested as previously described. The splenocytes were
washed twice with complete RPMI (500 × g, 5 minutes)
then suspended in RPMI (107  cells/ml). Splenocytes
(106cells/well) were added to each well of a 96-well flat
bottom plate and incubated with the irrelevant peptide or
HPV 16 E7 peptides at a final concentration of 3 μg/ml.
Duplicates were prepared for each peptide, then plates
were incubated for 6 hours at 37°C/5 % CO2.
Intracellular cytokine staining used the procedure
described by the manufacturer (Cytofix Cytoperm™ kit,
BD Biosciences, Mississauga, ON). In brief, 2 hours after
addition of stimulants, Golgistop (1 μl) was added to each
well and the plates were incubated (37°C/5% CO2) for an
additional 4 hours. Cells were washed twice with staining
buffer (200 μl, 0.01% sodium azide and 1% bovine serum
albumin or 1% fetal calf serum in PBS). Cells were incu-
bated (20 minutes, 4°C, in the dark) with anti-CD8 FITC
conjugated antibody (1 μl), washed with staining buffer
and incubated (30 minutes at 4°C in the dark) with
Cytofix (50 μl). Finally cells were incubated with APC-
labeled anti-IFN-γ antibody (1 μl; 30 minutes at 4°C in
the dark). Unbound antibody was removed by washing,
cells were resuspended in perm/wash buffer and trans-
ferred to FACS tubes. Staining was assessed by FACSCali-
bur (BD Biosciences, San Jose, CA) and analyzed using
CellQuest software.
Statistical analysis
Data are expressed as the mean ± SD and statistical signif-
icance was determined using paired two-tailed Student t-
test (p < 0.05).
Results
Eradication of large TC1/A2 tumors
HLA-A2 transgenic mice represent a versatile animal
model for preclinical studies of HLA-A*0201 restricted
CTL responses and represent a mouse model which is
closer than C57BL6 for human cervical cancer. One limi-
tation of H-2-restricted studies is antigen processing,
therefore, human MHC class I epitopes can not be tested
in this system. HLA transgenic mice, however, may serve
as a bridge between the mouse and human MHC
restricted responses. Independent reports have demon-
strated that HLA-A*0201 transgenic mice recognize CTL
epitopes detected by human CD8+ T cells that express the
same MHC [14,15]. Straight A2 mice are more likely to
mount high affinity CTL responses against peptides since
the mouse CD8 molecules have a low affinity for human
HLA  α3 domains. Such weak binding suggest that an
effective interaction between CTLs and tumor cells
requires an overall high avidity which is likely to be pro-
vided by high affinity CTLs.
A major limitation of preclinical tumor immunotherapy
studies is their failure to reject well-established tumors
resulting in a very modest success rate when such studies
move into clinical trials. The microenvironment of early
stage tumors (3, 4, 5, or 6-day old) is different than the
microenvironment of advanced stage tumors which may
be more representative of human cancer. Here, we exam-
ined the ability of VM-formulated vaccines to reject 19-
day old tumors of large sizes.
To evaluate the therapeutic effect of vaccination against
peptide antigens delivered with VM, HLA-A2 mice were
implanted with TC1/A2 tumor cells that cause the estab-
lishment of large tumors by day 19 post-implantation.
Mice in four treatment groups received: 1) PBS, 2) E7: 82–
90 , 3) the mixture of four HPV E6/E7-derived peptides
(E7:11–20; E7: 82–90; E7: 86–93; E6: 29–38) that contain
human CTL epitopes or 4) the same four peptides fused
together in a long peptide (AB2). All mice injected with
PBS developed tumors (Fig. 1). Forty percent of mice vac-
cinated against E7: 82–90 carried tumors up to 60 days
post-tumor implanation when the trial was terminated. InJournal of Translational Medicine 2007, 5:26 http://www.translational-medicine.com/content/5/1/26
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contrast, all mice treated with a mixture of the four pep-
tides or the four peptides fused together were tumor-free
by day 60 post-tumor implantation.
Measurement of tumor size in individual mice indicated
that tumors were eradicated at different rates in individual
mice (Fig. 2). Tumor growth was similar in all mice in the
control group that received PBS (Fig, 2A). Of the four pep-
tides in the mixture, E7: 82–90 was selected as having the
most potential to produce specific CTL responses based
on intracellular cytokine staining and ELISPOT results
(see Fig. 3 &4). Immunization against E7: 82–90 reduced
tumor size but only eradicated the tumor of one mouse by
day 40 post-tumor implantation (Fig. 2B). Tumors that
were reduced in size in the other four mice, increased in
size after day 40. Immunization with the peptide mixture
caused tumor eradication by day 25 in one mouse, by day
30 in another mouse and in the remaining 3 mice by day
40 (Fig. 2C). Similarly, immunization with the long pep-
tide caused tumor eradication by day 25 in one mouse,
day 35 in another mouse and in the remaining 3 mice by
day 40 (Fig. 2D). The tumor in one mouse from the latter
group increased in size to 5500 mm3 before reduction in
tumor size was observed.
Intracellular cytokine staining
To measure the relative ability of each peptide in the four
peptide mixture to induce a CTL response, mice were
immunized by a single administration of each peptide in
the mixture alone or a mixture of the four peptides in VM.
Fourteen days post-immunization, splenocytes were cul-
tured for 6 h in the presence of each peptide, the peptide
mixture (in accordance with the immunization regime) or
without added peptide. Ex vivo intracellular IFN-γ staining
of splenocytes from mice immunized against E7: 82–90
demonstrated that the proportion of IFN-γ positive CD8+
T-cells was higher (1.13% of splenocytes) when spleno-
cytes were exposed to E7: 82–90 compared to no exposure
to exogenous peptide (0.10% of splenocytes; Fig. 3). The
proportion of IFN-γ positive CD8 + T-cells in splenocytes
from mice immunized against the peptide mixture and
stimulated with the peptide mixture was similar (1.03%
of splenocytes). The proportion of IFN-γ positive CD8 +
cells in splenocytes from mice immunized against E7: 11–
Immunization of mice against the four peptide mixture derived from HPV 16 E6/E7 proteins of type 16 HPV (squares) or the  same peptides joined together in a long peptide (diamonds) eradicated tumors from all treated mice Figure 1
Immunization of mice against the four peptide mixture derived from HPV 16 E6/E7 proteins of type 16 HPV (squares) or the 
same peptides joined together in a long peptide (diamonds) eradicated tumors from all treated mice. Immunization of mice 
against a single peptide E7: 82–90 eradicated TC1/A2 tumors from 60% of treated mice (triangles). In contrast, all mice that 
received PBS developed tumors (crosses). These results suggest that immunization against more than one peptide antigen 
results in increased eradication of tumors and that multiple peptide antigens can be administered as a mixture or fused into 
one peptide.Journal of Translational Medicine 2007, 5:26 http://www.translational-medicine.com/content/5/1/26
Page 5 of 9
(page number not for citation purposes)
20, E7: 86–93 or E6: 29–38 and stimulated with homolo-
gous peptide were 0.65, 0.18 and 0.12 % of splenocytes
respectively (Fig. 4). The results indicate that E7: 82–90
peptide induced the strongest CTL response.
Discussion
Malignancies pose a burden on health worldwide but in
particular for the elderly. High morbidity and mortality
are attributable to limited current therapies, therefore,
there is a need for a new generation of vaccines that are
cost effective, safer and yet mount robust, effective and
durable immune responses [16]. While in general, vac-
cines are beneficial for the elderly, there is a need to
improve vaccine efficacy for people of advanced age [4,5].
Previously, we reported that a single vaccination of a HPV
16 E7-derived peptide coupled to PADRE in VM induces
immune responses that are efficacious, potent, safe and
durable [6]. To extend these results to a more clinically
appropriate HPV cancer model, the TC1/A2 and HLF 16
tumor cell lines in aged HLA-A2 transgenic mice were cho-
sen. This model requires the use of peptide antigens that
are presented by HLA-A*0201 and serves as a bridge
between pre-clinical and phase I clinical trials. Previous
studies that used the TC1/A2 or HLF-16 in this humanized
mice model reported a prophylactic or prophylactic/ther-
apeutic benefit from vaccination respectively suggesting
that cancer immunotherapy offers promise [9,12,13].
However, this is the first report demonstrating rejection of
large established 19-day old TC1/A2 tumors in mice of
advanced age. The results reported in this study indicate
that effective immunotherapy against human cervical can-
cer is possible. In particular, this study used VM to admin-
ister four peptides as a mixture or as a single peptide
formed by coupling the four peptides together. Both treat-
ments resulted in eradication of tumors from all treated
mice. Furthermore, none of these mice developed tumors
Development of TC1/A2 tumors in five mice treated with PBS (panel A), E7: 82–90 (panel B), peptide mixture (panel C) or  fused peptide (AB2; panel D) Figure 2
Development of TC1/A2 tumors in five mice treated with PBS (panel A), E7: 82–90 (panel B), peptide mixture (panel C) or 
fused peptide (AB2; panel D). The arrows indicate time of vaccination.Journal of Translational Medicine 2007, 5:26 http://www.translational-medicine.com/content/5/1/26
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when re-challenged with 107 HLF-16 tumor cells, which is
a different HLA-A2/E6/E7 expressing tumor cell line. This
suggests that the cytotoxic immune response generated
with VM was robust enough to prevent regeneration of
any of the potentially eradicated tumors.
The antigens employed in this report are an improvement
over the antigen composition previously reported [6].
Hitherto, the antigen was chemically coupled to PADRE
as a means of keeping antigen and adjuvant together. The
liposomes in VM have the potential advantage of keeping
all vaccine ingredients together by encapsulation. Eradica-
tion of tumors by vaccines described in this report sug-
gests that chemical coupling of antigen to PADRE is not
essential for a successful cancer vaccine and that encapsu-
lation of vaccine ingredients in VM is sufficient to stimu-
late PADRE-induced T cell help for the expansion of CTL
responses. Likewise, chemical coupling of peptide anti-
gens is unnecessary for an effective multiple-peptide
based vaccine provided VM is used in vaccine delivery.
In summary, the VM vaccine platform containing peptide
antigens in two different formats, namely a mixture of sin-
gle peptides or the same peptides linked together in a sin-
gle long peptide induces a robust CTL response. The
immune responses induced by each peptide antigen for-
mat were shown to be highly efficacious using a cancer
model based on humanized mice of advanced age.
Ex vivo intracellular IFN-γ staining of splenocytes from mice immunized against E7: 82–90 alone or a mixture of four peptides  consisting of E7: 11–20, E7: 82–92, E7: 86–93 and E6: 29–38 Figure 3
Ex vivo intracellular IFN-γ staining of splenocytes from mice immunized against E7: 82–90 alone or a mixture of four peptides 
consisting of E7: 11–20, E7: 82–92, E7: 86–93 and E6: 29–38. Splenocytes not stimulated with exogenous peptide produced 
background levels of IFN-γ staining splenocytes (panel A). Only immunization against E7: 82–90 (panel B) or a mixture of the 
four peptides (panel C) caused expansion of CD8 +/IFN-γ + T-cells above background levels.Journal of Translational Medicine 2007, 5:26 http://www.translational-medicine.com/content/5/1/26
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